Elexacaftor/tezacaftor/ivacaftor corrects salt-wasting in cystic fibrosis
In pwCF, ETI treatment improves NaCl and fluid conservation. Future guidelines should consider an increased risk for cardiovascular disease in pwCF after initiation of CFTR modulator treatment. Salt repletion appears unnecessary in ETI-treated pwCF.
Authors
- Richard Warth (ORCID: https://orcid.org/0000-0001-6084-0659)
- Søren Jensen‐Fangel
- Majbritt Jeppesen
- Mads Vaarby Sørensen (ORCID: https://orcid.org/0000-0001-6398-1035)
- Jens Leipziger (ORCID: https://orcid.org/0000-0002-6719-7034)
- Sascha Bandulik (ORCID: https://orcid.org/0000-0001-7955-7220)
- Amalie Quist Rousing (ORCID: https://orcid.org/0009-0005-8762-4733)
- Peder Berg (ORCID: https://orcid.org/0000-0002-5216-2891)
Institutions
- Aarhus University (DK)
- Aarhus University Hospital (DK)
- University Hospital Regensburg (DE)
- University of Regensburg (DE)
Publication Details
- Journal
- Journal of Cystic Fibrosis
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1016/j.jcf.2025.12.006
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.52